Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bluebird Bio Gets Relief, But Gene Therapy Hurdles Remain

Sickle Cell Patient’s AML Likely Unrelated To LentiGlobin

Executive Summary

The jury is still out on the case of MDS and some remaining questions regarding the AML case may still hinder commercial uptake.

You may also be interested in...



Single Patient Safety Concern Hits Allogene’s Off-The-Shelf CAR-T

Allogene is the frontrunner in the allogeneic CAR-T field but must assess whether or not its therapy could have caused a patient’s unexpected chromosomal abnormality.

Adverum Halts Phase II Gene Therapy Trial After Patient’s Vision Loss

Slated to begin a Phase III later this year of ADVM-022 in wet AMD, Adverum had to scuttle a Phase II study of the gene therapy in DME after a patient suffered ocular hypotension, panuveitis and vision loss in the treated eye.

Bluebird’s Latest Gene Therapy Stumble Will Help Vertex Close The Gap

Once the darling of biotech investors, Bluebird Bio’s go-it-alone strategy with Zynteglo has not paid off as German launch plans stall.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel